Three-Year Clinical Outcomes in Geographic Atrophy: An Analysis of 18,712 Patient Eyes.

Methods: Retrospective analysis of 18,712 eyes with GA using the CorEvitas Vestrum Health Retina Database.

Results: Mean age at index was 78.6 years (SD = 7.

Safety and Tolerability of Suprachoroidal Axitinib Injectable Suspension, for Neovascular Age-related Macular Degeneration; Phase I/IIa Open-Label, Dose-Escalation Trial.

Purpose: To evaluate the safety and tolerability of a single dose of axitinib injectable suspension (CLS-AX), a pan-anti-VEGF tyrosine kinase inhibitor (TKI), administered via suprachoroidal injection in patients with neovascular age-related macular degeneration (nAMD).

Design: Phase I/IIa, open-label, sequential dose escalation.

Participants: Anti-VEGF treatment-experienced patients with active subfoveal choroidal neovascularization secondary to nAMD.

Suprachoroidal Drug Delivery for Macular Edema Associated With Noninfectious Uveitis.

To evaluate clinical trials in the literature that focus on suprachoroidal drug delivery for the treatment of noninfectious uveitis and other posterior segment diseases. A synthesis of the literature was performed. In 2021, suprachoroidal space triamcinolone acetonide, a corticosteroid delivery system used for the treatment of uveitic macular edema (ME), was approved by the US Food and Drug Administration.

Spectral-domain OCT characteristics of intraretinal hyper-reflective foci associated with age-related macular degeneration and diabetic retinopathy.

Objective: The purpose of this study was to quantitatively analyze and compare OCT characteristics of intraretinal hyper-reflective foci (IHRF) in eyes with diabetic retinopathy (DR) versus age-related macular degeneration (AMD).

Design: a retrospective observational study.

Participants: 54 treatment-naïve eyes (27 DR and 27 AMD).